An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI) (REVIVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01483898
Recruitment Status : Completed
First Posted : December 2, 2011
Last Update Posted : June 6, 2017
Information provided by (Responsible Party):
Vericel Corporation

November 30, 2011
December 2, 2011
June 6, 2017
February 2012
April 2014   (Final data collection date for primary outcome measure)
Amputation free survival (AFS) at 12 months post-injection [ Time Frame: 12 months ]
The primary objective will be to assess the efficacy of ixmyelocel-T compared to placebo (vehicle control) on AFS at 12 months post-injection in CLI patients with no options for revascularization. Amputation free survival is defined as time to the first occurrence of either major amputation (above the talus) in the index leg or all-cause mortality (death).
Same as current
Complete list of historical versions of study NCT01483898 on Archive Site
  • Percent of patients with adverse events [ Time Frame: 18 months ]
    A secondary objective will be to evaluate the overall safety and tolerability of ixmyelocel-T versus placebo in patients with CLI from time of aspiration through 18 months post-treatment/follow-up by % of patients with adverse events.
  • Percent of patients with complete wound closure by Month 12 [ Time Frame: 12 months ]
    A secondary objective is to assess the percent of patients with at least 1 ischemic wound on the index leg that is present at Visit 3 (preinjection) having complete closure by Month 12.
  • Percent of patients experiencing a major cardiac event (MACE) by Months 6, 12, and 18 [ Time Frame: 6, 12 and 18 months ]
    % of patients experiencing a MACE event defined as cardiovascular mortality, myocardial infarction, chest pain requiring hospitalization, or stroke.
Same as current
Not Provided
Not Provided
An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Ixmyelocel-T In Subjects With Critical Limb Ischemia And No Options For Revascularization
This study is designed to evaluate the efficacy and safety of ixmyelocel-T, a patient-specific expanded multicellular therapy, for the treatment of patients with critical limb ischemia (CLI). The study is a randomized, vehicle controlled (placebo)study in CLI patients who have no option for revascularization procedures. All patients randomized will undergo a small volume bone marrow aspiration in a 15-minute outpatient or in-office procedure. All patients will receive injections of either ixmyelocel-T or vehicle-control into their pre-identified index leg. Patients will be followed for 18 months.
Not Provided
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Critical Limb Ischemia
  • Biological: Ixmyelocel-T
    On Day 14, 20 intramuscular injections of either ixmyelocel-T or vehicle control on pre-identified index leg.
  • Other: Placebo
    On Day 14, 20 intramuscular injections of either ixmyelocel-T or vehicle control on pre-identified index leg.
  • Experimental: ixmyelocel-T
    Intervention: Biological: Ixmyelocel-T
  • Placebo Comparator: Placebo
    Intervention: Other: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
April 2014
April 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males and nonpregnant, nonlactating females
  • Ages 35 to 90 years of age
  • Diagnosis of CLI with tissue loss (corresponding to Rutherford Category 5; see Appendix B) having an ulcer size of at least 0.5 cm2, a smaller sized ulcer penetrating into the subcutaneous tissue, and/or gangrene (dry). In addition, the subject must have ONE of the following documented at screening:

    • Ankle systolic pressure < 70 mm Hg
    • Toe systolic pressure < 50 mm Hg
    • TcPO2 < 30 mm Hg (in a supine position)
  • Subjects must have no reasonable standard-of-care options for surgical or endovascular revascularization interventions
  • Subjects must have the following:

    • A narrative documenting the reasons why the site vascular specialist considers the subject "no option". A vascular specialist will be the principal investigator (PI) or subinvestigator and is defined as: vascular surgeon, interventional cardiologist, certified vascular medicine specialist, or interventional radiologist; AND
    • Secondary confirmation by an independent Eligibility Review Committee (ERC; see Section 8.1) after review of appropriate documents including, but not limited to: imaging results, medical records, surgical history, site vascular specialist narrative documenting reasons for "no option," and/or lab reports.
  • Major amputation in the index leg or death is not anticipated within 3 months of screening in the opinion of the vascular specialist (who must be the PI or subinvestigator)
  • In the opinion of the investigator, the subject is controlled on medical therapy indicated for CLI (unless there is a documented contraindication or intolerance)
  • Subject is current with all age-appropriate American Cancer Society (ACS) or similar (e.g., United States Preventative Service Task Force) screening guidelines
  • Given medical history and concurrent medication, the subject is an acceptable candidate for bone marrow aspiration and intramuscular injection procedures in the opinion of the Investigator
  • Subject is willing and able to comply with the scheduled visits, aspiration/injection procedure, wound care instructions treatment plan, and other study procedures for the duration of the study
  • Provide a personally-signed and dated informed consent document indicating that the subject (or a legally-acceptable representative, if permitted by the site's Investigational Review Board [IRB]) has been informed of all pertinent aspects of the study

Exclusion Criteria:

Patients presenting with any of the following will not be randomized:


  • Failed open surgical revascularization (on index leg) within 4 weeks of screening Visit 1
  • Acute limb-threatening ischemia, trauma, known non-atherosclerotic vascular disease (e.g., temporal/giant cell arteritis, Takayasu's arteritis, Raynaud's occlusive disease, Buerger's disease), embolic disease, aortoiliac disease with > 50% stenosis, or history of hypercoagulable states
  • Advanced CLI (i.e., nonsalvageable) defined as Rutherford Category 6
  • Clinical evidence of invasive infection in index leg (e.g., cellulitis, osteomyelitis, wet gangrene)
  • At screening, non-heel wound size of > 20 cm2 (excluding toe gangrene); or wounds on the heel > 10 cm2 on the index leg as measured by the Wound Core Lab (WCL) from photographs (and/or acetates) provided by the site
  • Previous amputation at or above the talus in the index leg Medical History
  • Hemoglobin A1c (HbA1c) ≥ 10% at screening
  • Diabetic subjects with uncontrolled or untreated proliferative retinopathy as determined by dilated eye exam (by qualified eye care professional as per American Diabetes Association guidelines)
  • Blood clotting disorder not caused by medication (e.g., thrombophilia)
  • Active non-basal cell cutaneous malignancy requiring surgery, chemotherapy, and/or radiation in the past 12 months
  • Current documented drug or alcohol abuse that would interfere with the subject's compliance with study procedures
  • Known allergies to any equine, porcine, or bovine products
  • Body mass index (BMI) ≥ 50 kg/m2 at screening
  • Established chronic kidney disease (CKD) requiring dialysis (Stage 5); estimated creatinine clearance < 15 mg/mL/min at screening
  • Systolic blood pressure (SBP) > 200 mm Hg or diastolic blood pressure (DBP) > 120 mm Hg or papilledema noted via ophthalmoscope at screening physical exam
  • Within 3 months prior to screening, a clinically significant history of cardiac disease

Laboratory Parameters:

  • Abnormal laboratory values (performed at central lab) at screening:

    • Platelets < 50,000 μL
    • Aspartate aminotransferase/alanine aminotransferase (AST/ALT) > 3 times the upper limit of normal (ULN)
    • Human immunodeficiency virus 1 (HIV 1), HIV 2, or syphilis positive (rapid plasma reagin [RPR])
    • Active hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV); Exclusionary Procedures, Devices, or Medication
  • Exposure to immunosuppressive therapy for oncologic or chronic non-oncologic reasons in the prior 12 months or expected requirement over the course of the study (e.g., chemotherapy, radiation therapy, methotrexate)
  • Concurrent participation in another clinical trial or receiving experimental medication within 30 days of screening or having previously been exposed to Aastrom's ixmyelocel T product [previously known as tissue repair cells (TRC), cardiac repair cells (CRC), vascular repair cells (VRC)]
  • On the index leg, use of concomitant wound treatments not currently approved for ischemic wound-healing within 30 days prior to screening or plans to initiate new, nonstandard-of-care treatments to the index leg during the study
Sexes Eligible for Study: All
35 Years to 90 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
ABI 55-1009-1
Not Provided
Plan to Share IPD: No
Vericel Corporation
Vericel Corporation
Not Provided
Not Provided
Vericel Corporation
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP